Pros | ![]() 5Y returns in the top 25% of the category. ![]() Among most bought funds within the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | 4/8 | 1/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 6 Years | 12 Years | ||
Fund Size | 3019 Cr | 3611 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹100 | SIP ₹500 Lumpsum ₹5000 | ||
Expense Ratio | 0.63% | 0.9% | ||
Exit Load | 0.5% | 0.5% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 33 | 32 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (10.78%) Suven Pharmaceuticals Ltd (9.49%) Cipla Ltd (8.55%) Ipca Laboratories Ltd (7.98%) Globus Medical Inc Class A (5.58%) | Sun Pharmaceuticals Industries Ltd (13.45%) Max Healthcare Institute Ltd Ordinary Shares (6.68%) Divi's Laboratories Ltd (6%) Cipla Ltd (4.79%) Lupin Ltd (4.72%) | ||
No of Sectors | 2 | 2 | ||
Top 3 Sectors | Health (98.55%) Financial Services (1.45%) | Health (93.19%) Basic Materials (6.81%) | ||
Equity % | 99.18% | 96.96% | ||
Debt % | - | - | ||
P/E | 38.2 | 42.28 | ||
P/B | 4.87 | 5.85 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -1.64% | 4.06% | ||
3-Month Return | -7.59% | -0.43% | ||
6-Month Return | -8.15% | -0.93% | ||
1-Year Return | 18.7% | 21.64% | ||
3-Year Return | 20.1% | 23.93% | ||
5-Year Return | 26.35% | 26.46% |
Sharpe | 0.9 | 1.12 | ||
Alpha | 2.42 | 5.03 | ||
Beta | 0.87 | 0.85 | ||
Standard Deviation | 15.95 | 14.93 | ||
Information Ratio | 0.16 | 1 |
Description | DSP Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | SBI Healthcare Opportunities Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Chirag Dagli | Tanmaya Desai |